The Premium Business Information Source™
Report title:
DAEWOONG PHARMACEUTICAL CO. LTD.-COMPANY INSIGHT
from
TF Market Research
25 page report published Jul 14, 2008
Price
$960.00
available for immediate download
This report is also available for purchase on a
per-page basis
.
Report Overview
Purchase by Section
Search Inside
About TF Market Research
...Daewoong Pharmaceutical Co. Ltd is a manufacturer engaged in the provision of pharmaceutical products. The company was founded in #### with a mission to provide treatment and sa tisfaction to patients and families with high quality drugs. Its vision is to be a global healthcare group leading improvement in the quality of life. Daewoong's core technology offers Wound Healing-EGF (Epidermal Growth Factor) stimulating the entire woun d healing process, biopharmaceuticals-e fficient manufacturing system utilizing animal cells, microbes and viral vectors, new pharmac euticals-excellent antibody screening and edymetox systems, formulation and drug delivery system-susta ined release of peptides; stabilization of moisture- sensitive molecules by using double layer/core tablet s and chemical synthesis- synthesizing and purifying techniques produce value-added products. Daewoong offers products in four categories which include: Biopharmaceutical, New Chemical Entity (NCE), Drug...
Source:
LIFE SCIENCE ANALYTICS
Author:
HARINATHA, G.
Company:
DAEWOONG PHARMACEUTICAL CO LTD
Geographic Regions:
ASIA, EASTERN ASIA, KOREA, REPUBLIC OF
Non-Billable Page Numbers:
2
Format:
PDF
Sections
Title
Starting Page
Number of Pages
Company Information
1
1
Daewoong Pharmaceutical Co. Ltd. [NonUS -- Symbol : Stock Code Number : 069620 (KOE)]
1
1
Formation Date: 1945
1
1
Business Summary
1
1
Product Glance
3
1
Trial Phase
3
1
No of Products
3
2
Diseasehub Classification
3
1
Disease Hub
4
1
Product Summary
4
1
Trial Phase Source Partner
4
2
Condition Treated
5
1
Products
5
1
Product Details
5
1
1. Perivar Disease Hub Description
5
1
Therapeutic Indication Current Trial Trial Details Last Updated
5
1
2. Smecta Disease Hub Description
6
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 3. Erdos Disease Hub Description
6
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 4. Tiropa Disease Hub Description
6
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 5. Asacol Disease Hub Description
6
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 6. Gasmotin Disease Hub Description
6
1
Therapeutic Indication Current Trial Trial Details
6
1
Last Updated Partnering Details
7
1
7. Tenstaten Disease Hub Description
7
1
Therapeutic Indication Drug Class Current Trial M Trial Details Last Updated 8. Dynacirc SRO Disease Hub Description
7
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 9. Olmetec Disease Hub Description
7
1
Therapeutic Indication Drug Class Current Trial M Trial Details Last Updated 10. Methycobal Disease Hub Description
7
1
Therapeutic Indication Current Trial Trial Details Last Updated 11. Gluriad Disease Hub Description
8
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 12. Diabex Disease Hub Description
8
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 13. Airtal Disease Hub Description
8
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 14. Fenopron Disease Hub Description
8
1
Therapeutic Indication Current Trial Trial Details Last Updated 15. Rize Disease Hub Description
8
1
Therapeutic Indication Current Trial Trial Details Last Updated 16. Gliatilin Disease Hub Description
9
1
Therapeutic Indication Current Trial Trial Details Last Updated 17. Chicclean Disease Hub Description
9
1
Therapeutic Indication Current Trial Trial Details Last Updated 18. Chicclean Disease Hub Description
9
1
Therapeutic Indication Current Trial Trial Details Last Updated 19. Easyef Disease Hub Description
9
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 20. Asacol Disease Hub Description
9
1
Therapeutic Indication Current Trial Trial Details
9
1
Last Updated Partnering Details
10
2
21. Olmetec Plus Disease Hub Description
10
1
Therapeutic Indication Drug Class Current Trial Trial Details
10
1
Last Updated 22. Lipice Disease Hub Description
10
1
Therapeutic Indication Current Trial Trial Details Last Updated 24. Botox Disease Hub Description
10
1
Therapeutic Indication Current Trial Trial Details Last Updated 25. Nicostop Disease Hub Description
10
1
Therapeutic Indication Drug Class
10
1
Current Trial Trial Details
11
1
Last Updated 26. Levulan PDT Disease Hub Description
11
1
Therapeutic Indication Current Trial Trial Details
11
1
27. Allelock Disease Hub Description
11
1
Therapeutic Indication
11
1
Current Trial Trial Details Last Updated 28. Ursa Disease Hub Description
12
1
Therapeutic Indication Liver Current Trial M Trial Details Last Updated 29. Ursa complex Disease Hub Description Ursa
12
1
Therapeutic Indication Current Trial Trial Details Last Updated 30. Plunazol Disease Hub Description
12
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 31. Caretropin Disease Hub Description
12
1
Therapeutic Indication Growth Drug Class Hormone Current Trial PA Trial Details Presently it Last Updated 5/14/2008 32. rh-EP
12
1
Therapeutic Indication Drug Class Current Trial
12
1
Trial Details Presently it is Last Updated 5/17/2008 33. Catrix wound dressing Disease Hub Dermatology Description Catrix Wou
13
1
Therapeutic Indication Current Trial Trial Details
13
1
Last Updated Partnering Details
13
1
34. Easyef Disease Hub Description
13
1
Therapeutic Indication Current Trial Trial Details Last Updated 35. Easyef Disease Hub Description
13
1
Therapeutic Indication Mucositis Current Trial II Trial Details Presently it is in Last Updated 5/17/2008 36. Tamsulosin SR D
13
1
Therapeutic Indication Benign Prostatic Current Trial I Trial Details Presently it is in Last Updated 5/15/2008 37. Doxazosin
14
1
Therapeutic Indication Current Trial Trial Details Last Updated 41. DWP418 Disease Hub Description
14
1
Therapeutic Indication Multiple Sclerosis Current Trial PC Trial Details Presently it is in Last Updated 5/11/2008 46. Phense
15
1
Therapeutic Indication Drug Class Current Trial Trial Details
15
3
Last Updated Partnering Details
18
1
47. Easyef Disease Hub Description
18
1
Therapeutic Indication Current Trial Trial Details Last Updated 48. Easyef Disease Hub Description
19
1
Therapeutic Indication Current Trial Trial Details Last Updated 49. DWP423 Disease Hub Description
19
1
Therapeutic Indication Infectious Current Trial NA Trial Details Presently it Last Updated 4/3/2007 50. DWP-404 / DWP40458 Di
19
1
Therapeutic Indication Current Trial Trial Details
19
1
Last Updated
19
1
Corporate Partners
20
1
Deal Category: Product Date Source
20
1
Partner
20
2
Management Profile
22
1
Yoon, Yeong Hwan -- Chairman
22
1
Yoon, Jae Seung -- Vice Chairman and Chief Executive Officer
22
1
Lee, Jong Wook -- Chief Executive Officer
22
1
Koh, Yea-Wook -- General manager, R&D Center
22
1
Choi, Soo Jin -- General Manager, R&D Center
22
1
Park, Jae Hong -- Managing Director
22
1
2/11/2008 -- Daewoong Pharmaceutical, selected as a distinguished company of favorable labor- management relations
23
1
10/6/2005 -- The Health and Welfare Committee Of The National Assembly Visited Daewoong Pharmaceutical Hyangnam Factory
23
1
9/21/2005 -- Making High Quality Drug-'Differentiated Purchasing System'
23
1
9/2/2005 -- Success Story Of Coenzyme Q10 Development
23
1
5/6/2005 -- Easyef (Ingredient: EGF) With Excellent Effect Upon Treatment Of Chronic Injury And Scar Inhibition
23
1
3/29/2005 -- Daewoong Pharmaceutical Implements SRM System As Strategic Advanced Purchase Infra
23
1
9/21/2004 -- New Concept Anti-wrinkle Cosmetics Containing EGF Was Approved
23
1
8/31/2005 -- Joint Research On Alternative Medicine To Therapeutic Antibodies With Scotch Haptogen
24
1
5/16/2005 -- Haptogen Announce Landmark Collaboration with DaeWoong Pharmaceuticals to Develop Novel Anti-infectives
24
1
3/25/2005 -- New And Excellent ARB Hypertension Therapy "Olmetec Plus" Was Released
24
1
12/22/2004 -- Lescarden Enters Into Distribution Agreement for Catrix Wound Dressing in Korea
24
1
1/23/2003 -- Tillotts Pharma License Out the Rights of Asacol in South-Korea
24
1
5/10/1999 -- Dainippon Licenses Gasmotin to Daewoong of South Korea
24
1
2/1/1992 -- Allelix Supplies Epidermal Growth Factor to Daewoong
24
1
Intellectual Property
25
1
12/11/2006 -- Moxicle Patented Core Tablet Manufacturing Technology
25
1
8/24/2004 -- Obtained Patent Related With Development Of Platelet Therapy
25
1
Product Update
25
1
5/15/2007 -- Eisai Submits Application for Gastroprokinetic Agent Gasmotin in Thailand
25
1
Regulatory
25
1
10/3/2007 -- DUSA's Levulan Kerastick Receives Marketing Approval in Korea
25
1
Enter the keyword(s) which you would like to search for within this document and click "Search"
TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.
Price: $960.00
Questions about
this research?
Send page to a friend
Return to
Alacra Country Snapshot
Can't Decide?
Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our
FAQ
or ask our
Customer Service Team
any questions about the report you are considering purchasing.